Clinical trials: Somatosensory Disorders
- Condition Somatosensory Disorders
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Infant, Extremely Premature, Length of Stay
Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding
The primary hypothesis is that the preterm infants (26 0/7 to 30 6/7 weeks gestational age) who undergo the NTrainer System® training will transition to full oral feeds faster than the control group (i.e.
- Conditions
- Infant, Extremely Premature, Length of Stay, Feeding
- Trial name
- NCT01158391
- Testing
- NTrainer® Intervention, Control Intervention
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- KC BioMediX, Inc
Soft Tissue Anesthesia (Numbness)
Safety and Efficacy Study of NV-101 in Dental Patients
The purpose of this study was: to determine if NV-101 accelerates recovery from numbness compared to placebo to evaluate safety of NV-101
- Trial name
- NCT00154167
- Testing
- NV-101 (phentolamine mesylate solution)
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Novalar Pharmaceuticals, Inc.
Preterm Birth
Oral Entrainment on Suck Development of Preterm Infants Born 23 to 34 Weeks Gestational Age (GA)
The development of sucking behaviors in preterm infants is thought to reflect neurobehavioral maturation and organization. From a clinical perspective, the ability to feed depends upon a coordinated sucking, swallowing and…
- Trial name
- NCT01069744
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- KC BioMediX, Inc
Anesthesia, Dental
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Maxillary Procedures
This Phase 3 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the efficacy, pharmacodynamics, and safety of NV-101 administered as a submucosal injection following completion of a…
- Trial name
- NCT00309335
- Testing
- Phentolamine Mesylate (NV-101)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Novalar Pharmaceuticals, Inc.
Anesthesia, Dental
Study of NV-101 for Safety and Efficacy in Pediatric Dental Patients Undergoing Procedures
This Phase 2 clinical study is designed as a multicenter, randomized, blinded, controlled study to evaluate the safety and efficacy of NV-101 in approximately 150 children 4 to 11 years of age.
- Trial name
- NCT00309322
- Testing
- Phentolamine Mesylate (NV-101)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Novalar Pharmaceuticals, Inc.
Anesthesia, Dental
Study of NV-101 for Efficacy, Pharmacodynamics, and Safety in Dental Patients Undergoing Mandibular Procedures
This Phase 3 study is designed as a multicenter, randomized, blinded, controlled study to evaluate the efficacy, pharmacodynamics, and safety of NV-101 administered as a submucosal injection following completion of a restorative…
- Trial name
- NCT00309361
- Testing
- Phentolamine Mesylate (NV-101)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Novalar Pharmaceuticals, Inc.
Preterm Birth
Evaluating Patterned Oral Somatosensory Entrainment Stimulation Using the NTrainer on Oral Feeding Performance
This is a research study to determine if an experimental device called the NTrainer can improve oral feeding skills more quickly and more effectively than traditional methods in infants who are at high risk of feeding dysfunction…
- Trial name
- NCT01069718
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- KC BioMediX, Inc
Atopic Dermatitis
Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.
- Trial name
- NCT07014007
- Testing
- RV4421B- EV0407
- Where
- Mauritius
- Volunteers
- 105 people
- Sponsor
- Pierre Fabre Dermo Cosmetique